Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C9H13NO.BrH |
| Molecular Weight | 232.118 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Br.CC(N)CC1=CC=C(O)C=C1
InChI
InChIKey=RZCJLMTXBMNRAD-UHFFFAOYSA-N
InChI=1S/C9H13NO.BrH/c1-7(10)6-8-2-4-9(11)5-3-8;/h2-5,7,11H,6,10H2,1H3;1H
| Molecular Formula | BrH |
| Molecular Weight | 80.912 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C9H13NO |
| Molecular Weight | 151.2056 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Hydroxyamphetamine is a derivative of amphetamines. Hydroxyamphetamine is intended mainly as local eye drops for diagnostic purposes. It is indirect sympathomimetic agent which cause dilation of the eye pupil before diagnostic test. Among the minor side effects from its use are: change in color vision, difficulty seeing at night, dry mouth, headache, increased sensitivity of eyes to sunlight, muscle stiffness or tightness and temporary stinging in the eyes. The main use of hydroxyamphetamines as eye drops is the diagnosis of Horner's syndrome which is characterized by nerve lesions. Hydroxyamphetamine hydrobromide is a component of FDA approved brand drug - Paremyd sterile ophthalmic solution (Hydroxyamphetamine hydrobromide, USP 1.0%, Tropicamide, USP 0.25%). Hydroxyamphetamine is an indirect-acting sympathomimetic, while tropicamide acts as a parasympatholytic.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Diagnostic | Paremyd Approved UsePAREMYD Solution is indicated for mydriasis in routine diagnostic procedures and in conditions
where short-term pupil dilation is desired. PAREMYD provides clinically significant mydriasis with
partial cycloplegia. Launch Date1992 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.8 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/13143480/ |
10 mg/kg bw single, intravenous dose: 10 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered: |
HYDROXYAMPHETAMINE plasma | Canis lupus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
4 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/13143480/ |
10 mg/kg bw single, intravenous dose: 10 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered: |
HYDROXYAMPHETAMINE plasma | Canis lupus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/13143480/ |
10 mg/kg bw single, intravenous dose: 10 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered: |
HYDROXYAMPHETAMINE plasma | Canis lupus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Screening for and validated quantification of amphetamines and of amphetamine- and piperazine-derived designer drugs in human blood plasma by gas chromatography/mass spectrometry. | 2003 Jun |
|
| False negative hydroxyamphetamine test in horner syndrome caused by acute internal carotid artery dissection. | 2003 Mar |
|
| A study of the metabolism of methamphetamine and 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in isolated rat hepatocytes. | 2005 Mar 10 |
|
| Cation-selective exhaustive injection and sweeping MEKC for direct analysis of methamphetamine and its metabolites in urine. | 2006 Dec |
|
| Trace amine-associated receptor 1 displays species-dependent stereoselectivity for isomers of methamphetamine, amphetamine, and para-hydroxyamphetamine. | 2007 Apr |
|
| p-Hydroxyamphetamine causes prepulse inhibition disruptions in mice: contribution of dopamine neurotransmission. | 2010 Dec 25 |
|
| New meconium biomarkers of prenatal methamphetamine exposure increase identification of affected neonates. | 2010 May |
Patents
Sample Use Guides
Mydriasis: Ophthalmic: Instill 1 to 2 drops into conjunctival sac(s)
Route of Administration:
Topical
SH-SY5Y neurons were incubated with Hydroxyamphetamine (concentration range 0-10mM) for 24 or 48h, and the viability was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) and lactate dehydrogenase (LDH) leakage assays.. For Hydroxyamphetamine the TC50 was not reached in the tested concentration range. Hydroxyamphetamine at 8.00mM originated few late apoptotic cells
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:57:14 GMT 2023
by
admin
on
Fri Dec 15 18:57:14 GMT 2023
|
| Record UNII |
59IG47SZ0E
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29747
Created by
admin on Fri Dec 15 18:57:14 GMT 2023 , Edited by admin on Fri Dec 15 18:57:14 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
206-181-4
Created by
admin on Fri Dec 15 18:57:14 GMT 2023 , Edited by admin on Fri Dec 15 18:57:14 GMT 2023
|
PRIMARY | |||
|
m6117
Created by
admin on Fri Dec 15 18:57:14 GMT 2023 , Edited by admin on Fri Dec 15 18:57:14 GMT 2023
|
PRIMARY | Merck Index | ||
|
59IG47SZ0E
Created by
admin on Fri Dec 15 18:57:14 GMT 2023 , Edited by admin on Fri Dec 15 18:57:14 GMT 2023
|
PRIMARY | |||
|
CHEMBL1546
Created by
admin on Fri Dec 15 18:57:14 GMT 2023 , Edited by admin on Fri Dec 15 18:57:14 GMT 2023
|
PRIMARY | |||
|
100000086712
Created by
admin on Fri Dec 15 18:57:14 GMT 2023 , Edited by admin on Fri Dec 15 18:57:14 GMT 2023
|
PRIMARY | |||
|
SUB02581MIG
Created by
admin on Fri Dec 15 18:57:14 GMT 2023 , Edited by admin on Fri Dec 15 18:57:14 GMT 2023
|
PRIMARY | |||
|
DTXSID0045961
Created by
admin on Fri Dec 15 18:57:14 GMT 2023 , Edited by admin on Fri Dec 15 18:57:14 GMT 2023
|
PRIMARY | |||
|
59IG47SZ0E
Created by
admin on Fri Dec 15 18:57:14 GMT 2023 , Edited by admin on Fri Dec 15 18:57:14 GMT 2023
|
PRIMARY | |||
|
61065
Created by
admin on Fri Dec 15 18:57:14 GMT 2023 , Edited by admin on Fri Dec 15 18:57:14 GMT 2023
|
PRIMARY | |||
|
1325005
Created by
admin on Fri Dec 15 18:57:14 GMT 2023 , Edited by admin on Fri Dec 15 18:57:14 GMT 2023
|
PRIMARY | |||
|
C47558
Created by
admin on Fri Dec 15 18:57:14 GMT 2023 , Edited by admin on Fri Dec 15 18:57:14 GMT 2023
|
PRIMARY | |||
|
82066
Created by
admin on Fri Dec 15 18:57:14 GMT 2023 , Edited by admin on Fri Dec 15 18:57:14 GMT 2023
|
PRIMARY | RxNorm | ||
|
DBSALT001968
Created by
admin on Fri Dec 15 18:57:14 GMT 2023 , Edited by admin on Fri Dec 15 18:57:14 GMT 2023
|
PRIMARY | |||
|
9377
Created by
admin on Fri Dec 15 18:57:14 GMT 2023 , Edited by admin on Fri Dec 15 18:57:14 GMT 2023
|
PRIMARY | |||
|
306-21-8
Created by
admin on Fri Dec 15 18:57:14 GMT 2023 , Edited by admin on Fri Dec 15 18:57:14 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |